Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Citado por Google
- Similares en SciELO
- Similares en Google
Compartir
Acta Neurológica Colombiana
versión impresa ISSN 0120-8748versión On-line ISSN 2422-4022
Resumen
CARDENAS-ROBLEDO, Simón et al. Myelin oligodendrocyte glycoprotein antibody associated disease. Acta Neurol Colomb. [online]. 2023, vol.39, n.4, e5. Epub 19-Ene-2024. ISSN 0120-8748. https://doi.org/10.22379/anc.v39i4.854.
Introduction:
The disease associated with antibodies against the myelin oligodendrocyte glycoprotein (MOGAD) is a recently identified clinical entity, with unknown frequency, but is considered low compared to other demyelinating inflammatory diseases.
Materials And Methods:
Narrative review.
Results:
The clinical manifestations are heterogeneous, ranging from optic neuritis or myelitis to multi-focal CNS demyelination or cortical encephalitis. There have been described characteristic MRI features that increase the diagnostic suspicion, such as perineural optic nerve enhancement, spinal cord H-sign or T2-lesion resolution over time. The diagnosis is based on the detection of specific G- immunoglobulins against MOG, in the suggestive clinical context. Acute treatment is based on high dose steroids and maintenance treatment is generally reserved for relapsing cases or patients with severe residual disability after the first attack.
Conclusions:
In this narrative review, fundamental aspects of pathophysiology, clinical and radiological manifestations, diagnosis and treatment of MOGAD are discussed.
Palabras clave : Myelin-oligodendrocyte glycoprotein; Optic neuritis; Myelitis; Magnetic resonance imaging; Serology; Immunosuppression.